3.Discussion and Prospect
Lung illnesses frequently do not occur in isolation; instead, they may develop in combination with other systemic diseases, or numerous lung diseases may occur simultaneously, or due to a causative factor causes the disease to appear in diverse processes with varying clinical symptoms and disease types.  Microorganisms, for example, might cause pneumonia at an early stage, but severe pneumonia may cause ARDS or even a systemic inflammatory response syndrome, which could lead to pulmonary fibrosis in a long term, pulmonary fibrosis increases the risk of lung cancer by 7% to 20%[121]. This review addresses the results and developments of lncRNA-miRNA interactions in the development, prevention, and therapy of various common and thoroughly researched lung diseases. Some star lncRNA molecules have been extensively studied in a variety of diseases. MALAT1 and NEAT1, which are involved in acute and chronic inflammation of numerous causes of lung, as well as MALAT1 and HOTAIR, which are expressed in several tumors including lung cancer.
We further noticed that research into the mechanism of lncRNA-miRNA interactions in lung diseases is more focused on the ceRNA mechanism, in which lncRNA sponges binding miRNAs, suppresses miRNA binding, and silences downstream mRNA translation. Finding potential biomarkers for disease diagnosis, degree, prognosis, or targets for therapy required an understanding of the mechanism of lung disease formation and the role played by ncRNAs in the mechanism of cure. All of that is accomplished by constructing the lncRNA-miRNA action network. However, the involvement of lncRNA-miRNA interactions in lung diseases is a sophisticated network of inter-crosstalk among innumerable ncRNAs, the roles and processes of which are yet unclear.